• Drug: Envarsus XR (tacrolimus extended-release)
  • Manufacturer: Veloxis Pharmaceuticals

  • Route of Administration: Oral

  • Site of Care: Outpatient

  • Approved Indication:

    • prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants
    • prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants
  • Disease: solid organ transplant

  • Therapeutic Area: Infectious disease

  • Enrollment Form Link: www.envarsusxr.com/resources

  • Phone Number: 1-844-VELOXIS (1-844-835-6947)
  • Fax Number: 844-475-8931

  • Product Website: envarsusxr.com